SCHEMBL1666306

SCHEMBL1666306

CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1cccs1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.74
MAPT P10636 4/20 0.74
KMT2A Q03164 3/20 0.74
MEN1 O00255 2/20 0.74
KDM4E B2RXH2 8/20 0.67
CYP1A2 P05177 1/20 0.67
CYP3A4 P08684 1/20 0.67
GAA P10253 1/20 0.67
CYP2C9 P11712 1/20 0.67
CYP2C19 P33261 1/20 0.67
PKM P14618 1/20 0.67
HSD17B10 Q99714 3/20 0.66
HPGD P15428 2/20 0.66
TSHR P16473 2/20 0.66
ADORA2B P29275 3/20 0.65
LMNA P02545 1/20 0.65
POLB P06746 1/20 0.65
AGTR1 P30556 1/20 0.65
L3MBTL1 Q9Y468 1/20 0.61
ADORA3 P0DMS8 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7384754 0.90 ALDH1A1 (0.62) ALDH1A1MAPTKMT2AMEN1KDM4E
SCHEMBL7379493 0.90 ALDH1A1 (0.65) ALDH1A1MAPTKMT2AMEN1KDM4E
SCHEMBL7381171 0.87 ALDH1A1 (0.58) ALDH1A1MAPTKMT2AMEN1KDM4E
SCHEMBL11752901 0.85 ALDH1A1 (1.00) ALDH1A1MAPTKMT2AMEN1KDM4E
SCHEMBL10744169 0.85 ALDH1A1 (0.57) ALDH1A1MAPTKMT2AMEN1KDM4E
SCHEMBL3004313 0.85 ALDH1A1 (0.56) ALDH1A1MAPTKMT2AMEN1KDM4E
SCHEMBL4253439 0.85 ALDH1A1 (0.59) ALDH1A1MAPTKMT2AMEN1KDM4E
SCHEMBL7267057 0.83 L3MBTL1 (0.65) ALDH1A1MAPTKMT2AMEN1KDM4E
SCHEMBL9726304 0.83 ALDH1A1 (0.54) ALDH1A1MAPTKMT2AMEN1KDM4E
SCHEMBL7380520 0.82 KDM4E (0.71) ALDH1A1MAPTKMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8716319-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-05-06 US claimed
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-12-05 US claimed
CN-110683984-A Method for ultrasonically oxidizing hanster 1, 4-dihydropyridine derivative 阜阳师范大学 2020-01-14 CN disclosed
US-9045428-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2015-06-02 US disclosed
US-8716319-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-05-06 US disclosed
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-12-05 US disclosed
EP-0885192-B8 DIHYDROPYRIDINE-, PYRIDINE-, BENZOPYRAN- ONE- AND TRIAZOLOQUINAZOLINE DERIVATIVE, THEIR PREPARATION AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) 2012-05-16 EP disclosed
EP-2311806-A2 Dihydropyridine-, pyridine-, benzopyranone- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists The United States of America, Represented by the Secretary, Department of Health and Human Services (US) 2011-04-20 EP disclosed
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD PALO ALTO, INC. (US) 2010-08-05 US disclosed
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. 2009-07-16 US disclosed
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. 2009-01-08 US disclosed
US-6265127-B1 1, 4-dihydrophyridine charge control agents for electrostatographic toners and developers EASTMAN KODAK COMPANY 2001-07-24 US disclosed
EP-1109070-A2 1,4-Dihydropyridine charge control agents for electrostatographic toners and developers EASTMAN KODAK COMPANY (US) 2001-06-20 EP disclosed
US-6066642-A FOR SELECTIVELY BLOCKING THE A3 ADENOSINE RECEPTOR OF A MAMMAL THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2000-05-23 US disclosed
US-6048096-A PROCESSING THE FILM MATERIAL AFTER EXPOSURE WITH LIGHT EMITTED BY A GREEN-LIGHT EMITTING PHOSPHOR OF AN INTENSIFYING SCREEN AFTER CONVERSION OF X-RAYS HAVING ENERGY FROM 60 TO 150 KVP, IN AUTOMATIC PROCESSOR TO FORM AN IMAGE AGFA-GEVAERT, N.V. (BE) 2000-04-11 US disclosed
EP-0885192-A1 DIHYDROPYRIDINE-, PYRIDINE-, BENZOPYRAN- ONE- AND TRIAZOLOQUINAZOLINE DERIVATIVE, THEIR PREPARATION AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) 1998-12-23 EP disclosed
WO-1997027177-A2 DIHYDROPYRIDINE-, PYRIDINE-, BENZOPYRAN-4-ONE- AND TRIAZOLOQUINAZOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1997-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885MAPT 4314/4885KMT2A 2146/4885
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885MAPT 4314/4885KMT2A 2146/4885
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885MAPT 4314/4885KMT2A 2146/4885
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885MAPT 4314/4885KMT2A 2146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.